drugset
drugset / Trial / NCT02433119

The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

NCT02433119 ↗

Phase 4 Completed 238 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with valsartan 160mg monotherapy

Timeline

Start
2015-03-16
Primary completion
2016-09-08
Completion
2016-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Comparator Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Valsartan Small molecule 160 mg Oral

Indications

hypertensive disorder